Biomarker changes as surrogate endpoints in early‐phase trials in heart failure with reduced ejection fraction

Biomarker changes as surrogate endpoints in early‐phase trials in heart failure with reduced ejection fraction

Abstract Aims No biomarker has achieved widespread acceptance as a surrogate endpoint for early‐phase heart failure (HF) trials. We assessed whether changes over time in a panel of plasma biomarkers were associated with subsequent morbidity/mortality in HF with reduced ejection fraction (HFrEF). Met...

Full description

Bibliographic Details
Main Authors: Gianluigi Savarese, Alicia Uijl, Wouter Ouwerkerk, Jasper Tromp, Stefan D. Anker, Kenneth Dickstein, Camilla Hage, Carolyn S.P. Lam, Chim C. Lang, Marco Metra, Leong L. Ng, Nicola Orsini, Nilesh J. Samani, Dirk J. vanVeldhuisen, John G.F. Cleland, Adriaan A. Voors, Lars H. Lund
Format: Article
Language:English
Published: Wiley 2022-08-01
Series:ESC Heart Failure
Subjects:
Biomarkers
Surrogate endpoint
Surrogate outcome
Heart failure with reduced ejection fraction
Phase 2
Randomized trial
Online Access:https://doi.org/10.1002/ehf2.13917

Internet

https://doi.org/10.1002/ehf2.13917

Similar Items